Clinical-stage biopharma Aprea Therapeutics has filed for an initial public offering.
The filing comes via J.P. Morgan, Morgan Stanley, and RBC Capital Markets, with a placeholder registration for $86.25M.
It's seeking a Nasdaq listing under the symbol APRE.
Operating expenses for the six months ended June 30 were $10.35M. The company expects IPO proceeds and cash on hand to complete each of its ongoing clinical trials.
Subscribe for full text news in your inbox